Product Offerings
Products:
Phage-Based Feed Additives: Targeted bacteriophage solutions for combating drug-resistant bacteria in animal husbandry and agriculture.
Shandong New Line Biotechnology Co., Ltd., based in Weifang, China, is a pioneering high-tech enterprise specializing in the research, development, and production of bacteriophage-based biotechnology solutions for animal husbandry and agriculture. As a trailblazer in the commercialization of phage technology, the company has gained global recognition for providing next-generation, antibiotic-free feed additives designed to combat drug-resistant pathogens in livestock and poultry.
Core Business and Specialization
New Line Biotech is singularly focused on bacteriophage applications, offering a new paradigm in disease prevention and microbial balance in animal farming. Its core competencies lie in:
- Phage Isolation and Purification
- Phage-Based Feed Additives
- Microbial Precision Control
- Antibiotic Alternatives for Livestock and Poultry
Through advanced molecular biology and fermentation processes, the company delivers highly targeted and stable phage preparations designed to eliminate pathogenic bacteria without disrupting beneficial microbiota.
Flagship Products
Phage-Based Feed Additives
The company's primary offerings are customized phage formulations targeted at:
- Escherichia coli
- Salmonella spp.
- Clostridium perfringens
- Staphylococcus aureus
These solutions are used in poultry, swine, and aquaculture to prevent bacterial infections, improve gut health, and reduce mortality rates. Unlike antibiotics, phages offer a residue-free, resistance-proof, and highly specific alternative.
Product formats include:
- Microencapsulated powder
- Liquid concentrates for waterline delivery
- Customized phage cocktails for regional pathogen profiles
R&D and Technological Strength
New Line Biotech maintains a state-of-the-art research facility supported by partnerships with Chinese agricultural universities and international phage research networks. Their R&D focus areas include:
- Isolation of region-specific virulent phage strains
- Genome sequencing and virulence gene identification
- Encapsulation technologies for gastric acid protection
- Controlled release formulations for intestinal targeting
The company holds over 15 patents related to bacteriophage formulation and application technologies.
Manufacturing Capabilities
The company's production facility is designed according to GMP-like standards with capabilities for:
- High-capacity liquid and solid fermentation
- Phage purification and titer standardization
- Automated packaging and quality control
Their in-house QA/QC laboratories follow ISO 9001 protocols and test for phage potency (PFU/mL), specificity, stability, and microbial purity.
Quality and Certifications
New Line Biotech adheres to international quality standards and has secured:
- ISO 9001:2015 – Quality Management System
- ISO 22000:2018 – Food Safety Management (Applicable to feed additives)
- Veterinary Feed Additive Approvals – In select provinces and regions
- Export Registration – Compliant with APAC and Eastern Europe regulatory frameworks
The phage products are free from antibiotic residues, GMOs, and allergens, meeting rising global demand for sustainable and safe animal protein production.
Global Market Reach and Export Data
Shandong New Line Biotechnology has established its presence in global markets across:
- Southeast Asia: Vietnam, Thailand, Indonesia
- Middle East and Africa
- Eastern Europe
- South America
According to trade records and industry references:
- Export Shipments (2021–2023): Over 80 documented consignments
- Top Products: Phage additive for E. coli and Salmonella
- Distribution Channels: Veterinary pharmaceutical distributors, feed mills, and direct farm integrators
The company participates in global trade expos such as VIV Asia, EuroTier, and regional biotechnology conferences to promote its unique offerings.
Target Market and Clientele
New Line Biotech’s clientele includes:
- Commercial poultry and swine farms
- Veterinary pharmaceutical companies
- Antibiotic-free feed producers
- Livestock integrators
- Government-funded agricultural projects focused on antimicrobial resistance (AMR)
Their solutions are particularly suited for farms transitioning to antibiotic-free production systems while maintaining animal health and productivity.
Key Achievements
- 2022: Developed a microencapsulated phage product with proven efficacy in reducing mortality from Salmonella enterica by 68% in field trials
- 2021: Expanded manufacturing capacity with a new 3,000 m² GMP-grade fermentation facility
- 2020: Secured patent for broad-spectrum phage cocktail targeting E. coli and Clostridium spp.
- 2019: Received provincial award for innovation in antimicrobial resistance solutions
Brand Identity and Innovation Vision
Operating under the brand New Line, the company signifies a "new line" of defense in animal health—one that is natural, precision-targeted, and resistance-free. With its robust scientific foundation, regulatory credibility, and growing international footprint, Shandong New Line Biotechnology Co., Ltd. is positioned as a global leader in bacteriophage-based animal health solutions.